{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:55:46Z","timestamp":1791035746175,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.drup.2004.03.001","type":"journal-article","created":{"date-parts":[[2004,5,12]],"date-time":"2004-05-12T10:25:44Z","timestamp":1084357544000},"page":"125-138","source":"Crossref","is-referenced-by-count":66,"title":["Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives"],"prefix":"10.1016","volume":"7","author":[{"given":"Martin E","family":"Eichhorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Strieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Dellian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2004.03.001_BIB1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jnci\/6.1.73","article-title":"Vascular reactions of normal and malignant tissue in vivo","volume":"6","author":"Algire","year":"1945","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drup.2004.03.001_BIB2","first-page":"53","article-title":"Vascular reactions of normal and malignant tissues in vivo. II. The vascular reaction of normal and neoplastic tissues of mice to a bacterial polysaccharide from Serratia marescens (Bacillus prodigiousus) culture filtrates","volume":"8","author":"Algire","year":"1947","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drup.2004.03.001_BIB3","first-page":"39","article-title":"Molecular targeting of angiogenesis","volume":"1654","author":"Alessi","year":"2004","journal-title":"Biochem. Biophys. Acta"},{"key":"10.1016\/j.drup.2004.03.001_BIB4","first-page":"339","article-title":"Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression","volume":"147","author":"Augustin","year":"1995","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drup.2004.03.001_BIB5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/bies.950161208","article-title":"Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes","volume":"16","author":"Augustin","year":"1994","journal-title":"Bioessays"},{"key":"10.1016\/j.drup.2004.03.001_BIB6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(03)01018-0","article-title":"Antivascular therapy of cancer: DMXAA","volume":"4","author":"Baguley","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/nbm.723","article-title":"Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS","volume":"15","author":"Beauregard","year":"2002","journal-title":"NMR Biomed."},{"key":"10.1016\/j.drup.2004.03.001_BIB8","first-page":"1843","article-title":"The microtubule-affecting drug paclitaxel has antiangiogenic activity","volume":"2","author":"Belotti","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1172\/JCI5028","article-title":"Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal","volume":"103","author":"Benjamin","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2004.03.001_BIB10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI200317929","article-title":"Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors","volume":"111","author":"Bergers","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2004.03.001_BIB12","first-page":"355","article-title":"Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470","volume":"9","author":"Bhujwalla","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0361-090X(03)00030-8","article-title":"Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives","volume":"27","author":"Bisacchi","year":"2003","journal-title":"Cancer Detect. Prev."},{"key":"10.1016\/j.drup.2004.03.001_BIB14","first-page":"1974","article-title":"Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models","volume":"8","author":"Blakey","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1365-2362.1999.00534.x","article-title":"New strategies in anti-vascular cancer therapy","volume":"29","author":"Bloemendal","year":"1999","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.drup.2004.03.001_BIB16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/37126","article-title":"Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance","volume":"390","author":"Boehm","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.drup.2004.03.001_BIB17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ijc.10462","article-title":"Strategies for vascular targeting in tumors","volume":"100","author":"Brekken","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB18","first-page":"4221","article-title":"Vascular endothelial growth factor and vascular targeting of solid tumors","volume":"21","author":"Brekken","year":"2001","journal-title":"Anticancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin alpha v beta 3 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.drup.2004.03.001_BIB20","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1368-7646(03)00026-8","article-title":"Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences","volume":"6","author":"Broxterman","year":"2003","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.drup.2004.03.001_BIB22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/sj.bjc.6600141","article-title":"Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo","volume":"86","author":"Buerkle","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB23","doi-asserted-by":"crossref","first-page":"8996","DOI":"10.1073\/pnas.90.19.8996","article-title":"Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature","volume":"90","author":"Burrows","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.drup.2004.03.001_BIB24","first-page":"6831","article-title":"Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors","volume":"62","author":"Campbell","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB25","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.drup.2004.03.001_BIB26","first-page":"3304","article-title":"Induction of intra-tumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice","volume":"59","author":"Ching","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB27","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1200\/JCO.2003.05.100","article-title":"Functional imaging in phase I studies: decorations or decision making?","volume":"21","author":"Collins","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sj.bjc.6601035","article-title":"Surrogate markers in antiangiogenesis clinical trials","volume":"89","author":"Davis","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB29","first-page":"7247","article-title":"ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature","volume":"62","author":"Davis","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-0037-1613539","article-title":"Magnetic resonance imaging of tumor vasculature","volume":"89","author":"Degani","year":"2003","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drup.2004.03.001_BIB31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1055\/s-2002-33284","article-title":"Antivascular strategies\u2014a new concept for diagnosis and therapy of head and neck cancer. A review","volume":"81","author":"Dellian","year":"2002","journal-title":"Laryn. Rhino. Otol."},{"key":"10.1016\/j.drup.2004.03.001_BIB32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/02841868409136015","article-title":"Vascular endothelium as the vulnerable element in tumours","volume":"23","author":"Denekamp","year":"1984","journal-title":"Acta Radiol. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1046\/j.1365-2362.1999.00558.x","article-title":"The tumour microcirculation as a target in cancer therapy: a clearer perspective","volume":"29","author":"Denekamp","year":"1999","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.drup.2004.03.001_BIB34","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.2003.07.977","article-title":"Antiangiogenic therapy: more promise and, yet again, more questions","volume":"21","author":"Ellis","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjc.6601401","article-title":"Angiogenesis inhibitors in clinical development where are we now and where are we going?","volume":"90","author":"Eskens","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0093-7754(03)70024-4","article-title":"Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer","volume":"30","author":"Fernando","year":"2003","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/sonc.2002.37264","article-title":"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications","volume":"29","author":"Ferrara","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2004.03.001_BIB39","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2004.03.001_BIB40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","article-title":"What is the evidence that tumors are angiogenesis dependent?","volume":"82","author":"Folkman","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drup.2004.03.001_BIB41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/427787a","article-title":"Cancer without disease","volume":"427","author":"Folkman","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.drup.2004.03.001_BIB42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.133.2.275","article-title":"Isolation of a tumor factor responsible or angiogenesis","volume":"133","author":"Folkman","year":"1971","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2004.03.001_BIB43","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1200\/JCO.2003.05.187","article-title":"Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging","volume":"21","author":"Galbraith","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB44","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1200\/JCO.2002.09.144","article-title":"Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging","volume":"20","author":"Galbraith","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB45","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0140-6736(01)65002-5","article-title":"The growth of malignant disease in man and the lower animals with special reference to the vascular system","volume":"2","author":"Goldman","year":"1907","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2004.03.001_BIB46","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/bmj.318.7187.853","article-title":"Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment","volume":"318","author":"Hayes","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.drup.2004.03.001_BIB47","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1200\/JCO.2002.05.102","article-title":"Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin","volume":"20","author":"Herbst","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0093-7754(03)00269-0","article-title":"The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer","volume":"30","author":"Herbst","year":"2003","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/jnci\/94.12.883","article-title":"Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn\u2019t tell us","volume":"94","author":"Hlatky","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drup.2004.03.001_BIB50","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.drup.2004.03.001_BIB51","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1126\/science.1070200","article-title":"Tumor regression by targeted gene delivery to the neovasculature","volume":"296","author":"Hood","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.drup.2004.03.001_BIB52","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/sj.bjc.6601261","article-title":"Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis","volume":"89","author":"Hori","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB53","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/sj.bjc.6600296","article-title":"A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs","volume":"86","author":"Hori","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB54","first-page":"1433","article-title":"Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate","volume":"23","author":"Hua","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/1541-7786.36.2.1","article-title":"Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis","volume":"2","author":"Huang","year":"2004","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB56","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1126\/science.275.5299.547","article-title":"Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature","volume":"275","author":"Huang","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.drup.2004.03.001_BIB57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00046364","article-title":"Vascular and interstitial barriers to delivery of therapeutic agents in tumors","volume":"9","author":"Jain","year":"1990","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.drup.2004.03.001_BIB58","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2004.03.001_BIB59","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/sj.bjc.6600992","article-title":"Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent","volume":"88","author":"Jameson","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB60","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc905","article-title":"Clinical translation of angiogenesis inhibitors","volume":"2","author":"Kerbel","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/bies.950130106","article-title":"Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents","volume":"13","author":"Kerbel","year":"1991","journal-title":"Bioessays"},{"key":"10.1016\/j.drup.2004.03.001_BIB62","first-page":"45S","article-title":"Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results","volume":"19","author":"Kerbel","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB63","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.drup.2004.03.001_BIB64","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2004.03.001_BIB65","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ijc.11108","article-title":"Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels","volume":"105","author":"Krasnici","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB66","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2003.08.046","article-title":"Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416","volume":"21","author":"Kuenen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB67","first-page":"1648","article-title":"Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma","volume":"9","author":"Kuenen","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB68","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1523-1747.2003.12057.x","article-title":"Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a humanized SCID mouse model","volume":"120","author":"Kunstfeld","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.drup.2004.03.001_BIB69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3748\/wjg.v9.i2.193","article-title":"Current treatment for liver metastases from colorectal cancer","volume":"9","author":"Liu","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.drup.2004.03.001_BIB70","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.drup.2004.03.001_BIB71","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1024532022166","article-title":"Anti-angiogenic therapy: rationale, challenges and clinical studies","volume":"5","author":"Longo","year":"2002","journal-title":"Angiogenesis"},{"key":"10.1016\/j.drup.2004.03.001_BIB72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0093-7754(01)90047-8","article-title":"The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer","volume":"28","author":"Los","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB73","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nm0603-713","article-title":"Imaging of angiogenesis: from microscope to clinic","volume":"9","author":"McDonald","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2004.03.001_BIB74","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3816\/CBC.2003.n.007","article-title":"E2100: a phase III trial of paclitaxel versus paclitaxel\/bevacizumab for metastatic breast cancer","volume":"3","author":"Miller","year":"2003","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB75","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1200\/JCO.2003.08.092","article-title":"Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787\/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies","volume":"21","author":"Morgan","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB76","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1054\/drup.2000.0150","article-title":"Anti-angiogenesis therapy: concepts and importance of dosing schedules in clinical trials","volume":"4","author":"Mross","year":"2000","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.drup.2004.03.001_BIB77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00001622-200401000-00009","article-title":"Tumor endothelial markers: new targets for cancer therapy","volume":"16","author":"Nanda","year":"2004","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB78","first-page":"711","article-title":"Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice","volume":"61","author":"Nilsson","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB79","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/02713689209001812","article-title":"The effects of 5-fluorouracil and mitomycin C on the corneal endothelium","volume":"11","author":"Nuyts","year":"1992","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB80","first-page":"181","article-title":"Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model","volume":"5","author":"O\u2019Leary","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB81","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/(SICI)1097-0215(19971210)73:6<865::AID-IJC17>3.0.CO;2-3","article-title":"Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate","volume":"73","author":"Olson","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB82","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1054\/bjoc.2001.2157","article-title":"Quantitative imaging of tumour blood flow by contrast-enhanced magnetic resonance imaging","volume":"85","author":"Pahernik","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB83","first-page":"1323","article-title":"A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma","volume":"9","author":"Posey","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB84","first-page":"5209","article-title":"Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors","volume":"59","author":"Prewett","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB85","first-page":"6132","article-title":"Increased exposure of anionic phospholipids on the surface of tumor blood vessels","volume":"62","author":"Ran","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB86","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0360-3016(02)03928-7","article-title":"Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy","volume":"54","author":"Ran","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.drup.2004.03.001_BIB87","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1471-4914(02)00004-7","article-title":"Nanoparticle-mediated gene delivery to tumour neovasculature","volume":"9","author":"Reynolds","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.drup.2004.03.001_BIB88","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/sj.bjc.6600926","article-title":"Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging","volume":"88","author":"Robinson","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB89","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/scbi.2000.0334","article-title":"Targeting tumor vasculature with homing peptides from phage display","volume":"10","author":"Ruoslahti","year":"2000","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drup.2004.03.001_BIB90","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/sj.bjc.6600885","article-title":"5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study","volume":"88","author":"Rustin","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2004.03.001_BIB91","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2002.01.033","article-title":"Mechanisms and future directions for angiogenesis-based cancer therapies","volume":"20","author":"Scappaticci","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB92","first-page":"2335","article-title":"Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy","volume":"9","author":"Schmitt-Sody","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB93","first-page":"741","article-title":"Cilengitide Merck","volume":"4","author":"Smith","year":"2003","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.drup.2004.03.001_BIB94","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1200\/JCO.2003.12.986","article-title":"Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow","volume":"21","author":"Stevenson","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2004.03.001_BIB95","doi-asserted-by":"crossref","unstructured":"Strieth, S., Eichhorn, M., Sauer, B., Schulze, B., Teifel, M., Michaelis, U., Dellian, M., 2004. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int. J. Cancer. 110, 117\u2013124.","DOI":"10.1002\/ijc.20083"},{"key":"10.1016\/j.drup.2004.03.001_BIB96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1471-4914(02)00007-2","article-title":"Resistance in the anti-angiogenic era: nay-saying or a word of caution?","volume":"9","author":"Sweeney","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.drup.2004.03.001_BIB97","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1471-4892(01)00065-0","article-title":"Antiangiogenic and antivascular therapy for cancer","volume":"1","author":"Taraboletti","year":"2001","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.drup.2004.03.001_BIB98","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/1078-0432.CCR-0642-03","article-title":"Vascular targeting agents as cancer therapeutics","volume":"10","author":"Thorpe","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB99","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00666044","article-title":"Antibody-directed targeting of the vasculature of solid tumors","volume":"36","author":"Thorpe","year":"1995","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.drup.2004.03.001_BIB100","first-page":"1144","article-title":"The first international conference on vascular targeting: meeting overview","volume":"63","author":"Thorpe","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB101","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1172\/JCI965","article-title":"Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice","volume":"101","author":"Thurston","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2004.03.001_BIB102","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S","article-title":"Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols","volume":"10","author":"Tofts","year":"1999","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.drup.2004.03.001_BIB103","first-page":"6413","article-title":"Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability","volume":"61","author":"Tozer","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB104","first-page":"1626","article-title":"Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues","volume":"59","author":"Tozer","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB105","first-page":"1957","article-title":"Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction","volume":"9","author":"Wachsberger","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2004.03.001_BIB106","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1172\/JCI117857","article-title":"Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis","volume":"95","author":"Warren","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2004.03.001_BIB107","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2004.03.001_BIB108","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","article-title":"Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody","volume":"93","author":"Yuan","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.drup.2004.03.001_BIB109","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0168-3659(03)00236-0","article-title":"Mapping tumor vascular diversity by screening phage display libraries","volume":"91","author":"Zurita","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drup.2004.03.001_BIB110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/00313029400169411","article-title":"The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor","volume":"26","author":"Zwi","year":"1994","journal-title":"Pathology"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876460400024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876460400024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T16:48:03Z","timestamp":1682700483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S136876460400024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S136876460400024X"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2004.03.001","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}